Verastem Initiates Phase 1 Trial of Dual mTOR/PI3K Inhibitor
December 10, 2013 at 07:16 AM EST
Verastem (NASDAQ: VSTM ) today announced the initiation of a Phase 1 trial of VS-5584, a dual mTORC1/2 and PI3K inhibitor, in patients with advanced solid tumors or
